Incidence of Recurrent NASH-Related Allograft Cirrhosis

Shelly Kakar, Mohannad Dugum, Ricardo Cabello, Abhinav Humar, Jawad Ahmad, Shahid M. Malik

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Background: Cirrhosis secondary to nonalcoholic steatohepatitis (NASH) is projected to become the leading indication for liver transplantation (LT) in the USA in the next decade. The long-term implications of post-LT NASH, specifically on the development of allograft cirrhosis, are not well known. Methods: A retrospective cohort of patients at a single large center undergoing LT for NASH from 2000 to 2015 was identified using a prospectively collected database. A total of 226 patients undergoing LT for NASH were identified. Mean follow-up for the cohort was 7 years. Seventy-five percent of patients underwent at least one liver biopsy post-LT. Results: Eighty-one patients (36%) developed recurrence of biopsy-proven NASH. Fifteen patients developed bridging fibrosis but only four patients (1.8%) progressed to recurrent NASH cirrhosis at a mean of 9 years post-LT. Body mass index at the time of LT was statistically higher in the NASH allograft cirrhosis group. Recurrent disease was less common and less severe in those transplanted with black donors. All four patients with recurrent NASH cirrhosis developed evidence of portal hypertension, but all remained alive at follow-up. Conclusion: Although recurrent NASH following LT is common, the development of allograft cirrhosis is rare. These findings are useful when counseling patients and important to consider during their post-LT care.

Original languageEnglish
Pages (from-to)1356-1363
Number of pages8
JournalDigestive Diseases and Sciences
Issue number5
StatePublished - 15 May 2019


  • Allograft cirrhosis
  • Cirrhosis
  • Liver transplantation
  • NASH
  • Recurrent NASH


Dive into the research topics of 'Incidence of Recurrent NASH-Related Allograft Cirrhosis'. Together they form a unique fingerprint.

Cite this